ArticleThe Journal of investigative dermatology2017
Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro.
Article in The Journal of investigative dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.JID innovations : skin science from molecules to population health · 2025Trial
- Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.The Journal of investigative dermatology · 2022Trial
- Itch in dermatomyositis: the role of increased skin interleukin-31.The British journal of dermatology · 2018Trial
- Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies.Pharmaceutics · 2026Review
- CAR-T cell therapy in rheumatic diseases: a review article.Clinical rheumatology · 2026Review
- Geraniol modulates inflammatory and antioxidant pathways to mitigate intestinal ischemia-reperfusion injury in male rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.Annals of dermatology · 2024Review
- Green Smoke, Red Flag: Cannabis and the Risk of Orbitopathy and Dermopathy in Thyrotoxicosis.Cureus · 2023Article
- Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries.Frontiers in neurology · 2023Review
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.Cells · 2022Review
- Cannabinoids for the Treatment of Dermatologic Conditions.JID innovations : skin science from molecules to population health · 2022Review
- Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumArthritis research & therapy · 2022Article
- COL8A1 Promotes NSCLC Progression Through IFIT1/IFIT3-Mediated EGFR Activation.Frontiers in oncology · 2022Article
- Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.Journal of personalized medicine · 2021Review
- Pruritus in autoimmune connective tissue diseases.Annals of translational medicine · 2021Review
- TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease.Frontiers in neurology · 2021Review
- The Effect of Medical Cannabis on Pain Level and Quality of Sleep among Rheumatology Clinic Outpatients.Pain research & management · 2021Article
- Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases.Clinical drug investigation · 2020Review
- Thymoquinone reduces ischemia and reperfusion-induced intestinal injury in rats, through anti-oxidative and anti-inflammatory effects.Turkish journal of surgery · 2020Article
- Cannabinoids in the Pathophysiology of Skin Inflammation.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.